Plain-English translation of NCT06557265 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing , a new type of cell therapy that uses specially engineered natural killer cells to treat autoimmune kidney diseases. The medication is designed to target and calm down the immune system cells that are attacking the kidneys in lupus nephritis and primary membranous nephropathy. Researchers want to see if this treatment is safe and whether it can help people whose kidney disease hasn't responded to other therapies.
Many people with lupus nephritis and membranous nephropathy don't get better with current standard treatments, and their kidney function continues to decline. This trial exists to find a new option for patients who have tried multiple medications without success and are at risk of kidney failure.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first receive a preparatory treatment with two chemotherapy medications (fludarabine and cyclophosphamide) to prepare your body to accept the new cells. You will then receive three doses of , the experimental cell therapy. The study involves multiple visits to the hospital or clinic for infusions, blood tests, and monitoring of your kidney function and overall health over several months. Researchers will carefully watch for any side effects and measure whether your kidney disease improves.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States